PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Evolve’s Steven Gurney recognised in IAM 1000 2025

  • Technology: Patent law
  • 11th June 2025
We are delighted to announce that Evolve's founder Steven Gurney has once again been recognised in the IAM Patent 1000.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
IAM Patent 1000 logo

We are delighted to announce that Evolve’s founder Steven Gurney has once again been recognised in the IAM patent 1000. The IAM Patent 1000 rankings consider various factors such as expertise depth, market positioning, and positive feedback from both peers and clients.

A highly skilled life science patent attorney with over 20 years of combined in-house and private practice experience, Steven’s expertise spans pharmaceuticals, drug development and IP, drafting, portfolio management and prosecution, lifecycle management, licensing (in- and out-), due diligence and FTO, and contentious work.

We are grateful to IAM for once again highlighting Evolve in their Patent 1000 2025 Guide. We deeply appreciate our clients’ continued support and confidence, which has enabled this achievement.

Related insights...

Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Evolve Intellectual Property ranked in IAM Patent 1000

  • 13th September 2026
We are proud to announce that Evolve IP has been ranked in the 2026 publication of the IAM Patent 1000: United Kingdom – England and Wales. This year’s guide highlights our deep technical expertise in life sciences and our practical, strategic business focus. Congratulations to our patent attorneys, Steven Gurney who is ranked Silver and Rose Hughes who is…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

IP Stars: Evolve recognised in 2026 Publication

  • 13th September 2026
We are delighted to announce that Evolve IP has been recognised in the 2026 IP STARS rankings. This distinction reflects our team’s ongoing dedication to exceptional intellectual property support, featuring key individual accolades for our patent attorneys. Steven Gurney has been recognised as a Patent Star. This specific ranking is awarded to senior practitioners who demonstrate proven excellence in…
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Evolve Intellectual Property recognised in Legal 500 rankings

  • 13th September 2026
Evolve Intellectual Property is delighted to once again be recognised in the 2026 edition of Legal 500 for our growing specialised life science IP practice in Cambridge, UK. The publication highlights Steven Gurney (founder and European, UK, and Australian patent attorney) for his work protecting key biopharmaceutical assets and for his focus on complex prosecution…
Alice Walford Patent Attorney
Alice Walford Patent Attorney

Alice Walford joins Evolve

  • 1st July 2026
We are delighted to welcome Alice Walford to the Evolve team. Alice joins us with over 15 years of combined private practice and in-house experience in the life sciences sector. Alice brings a wealth of experience, including time at Novartis, Gyroscope Therapeutics and Abzena, working on gene therapies, small molecule and antibody assets. Her specialist…
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Evolve’s Claudia Greaves earns CIPA Advanced Patent Paralegal Qualification

  • 9th January 2026
We are delighted to announce that Evolve’s Claudia Greaves has recently passed the CIPA Advanced Patent Paralegal Course (APPC). Building on her six years of patent law experience, Claudia completed intensive modules that deepen her expertise in critical areas of IP management: The Patent Cooperation Treaty (PCT): Gaining in-depth understanding of both the International Phase…
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Evolve Intellectual Property celebrates 4 years!

  • 8th October 2025
Last month, Evolve celebrated its 4-year anniversary in style with a sparkling wine and canapés reception in Cambridge. Thank you to everyone who attended and for our clients’ continued trust and support. We look forward to many more years of helping our clients in their mission to deliver innovative medicines to market and bring hope…
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Launch of Evolve Webinars!

  • 25th June 2025
A series of live webinars on IP strategy for pharma & biotech professionals.
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy

  • 27th May 2025
Navigating European pharma and biotech patent litigation is more complex than ever, with ongoing debates on plausibility, UPC intricacies, claim interpretation, and divergent strategies for antibody inventions.
Rose Hughes
Rose Hughes

Rose Hughes joins Evolve

  • 7th May 2025
Evolve Intellectual Property is pleased to welcome Dr. Rose Hughes as our new Patent Attorney.
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Evolve joins the ranks of the Legal 500

  • 1st November 2024
We are delighted to announce that Evolve has joined the ranks of the Legal 500 Intellectual Property firms. The Legal 500 is one of the UK’s leading legal directories, known for its rigorous research methodology and independent analysis of the legal market. As a small boutique IP firm, we are particularly proud of this achievement. …
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice